Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 2/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | CTSA | P10619 | 2/20 | 0.38 |
| ▸ | DCAF1 | Q9Y4B6 | 2/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4517527 | 0.85 | CASP1 (0.42) | ALDH1A1CYP2D6TSHR | |
| SCHEMBL4511124 | 0.85 | CASP1 (0.42) | ALDH1A1CYP2D6TSHR | |
| SCHEMBL17846011 | 0.85 | CASP1 (0.42) | ALDH1A1CYP2D6TSHR | |
| SCHEMBL17846143 | 0.81 | MAPT (0.39) | ALDH1A1CYP2D6CTSAMAPK1 | |
| SCHEMBL4598226 | 0.78 | ROCK2 (0.50) | MEN1KMT2ACTSADCAF1 | |
| SCHEMBL4596498 | 0.78 | MAPK1 (0.51) | MEN1KMT2ACTSADCAF1MAPK1 | |
| SCHEMBL3446408 | 0.78 | MAPK1 (0.51) | MEN1KMT2ACTSADCAF1MAPK1 | |
| SCHEMBL14691111 | 0.76 | PHGDH (0.50) | ALDH1A1MEN1KMT2ACTSADCAF1 | |
| SCHEMBL17860065 | 0.76 | TACR1 (0.44) | CYP2D6HPGD | |
| SCHEMBL17685984 | 0.76 | MEN1 (0.44) | ALDH1A1MEN1KMT2ACTSADCAF1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3233859-B1 | BRIDGED PYRAZOLOPYRIDINE DERIVATIVES AS ERK INHIBITORS USEFUL FOR THE TREATEMENT OF CANCER | MERCK SHARP & DOHME (US) | 2019-08-07 | — | — | EP | disclosed |
| US-9988397-B2 | ERK inhibitors | MERCK SHARP & DOHME CORP. (US) | 2018-06-05 | — | — | US | disclosed |
| EP-3233859-A1 | ERK INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2017-10-25 | — | — | EP | disclosed |
| US-20170267695-A1 | ERK INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2017-09-21 | — | — | US | disclosed |
| WO-2016100051-A1 | ERK INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2016-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170267695-A1 | ERK INHIBITORS | MAPK1, MAP3K1, MAPK4 | ALDH1A1 331/4885CYP2D6 493/4885GAA 1958/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.